Julie VoseSource: ASCO.orgJULIE VOSE was elected president of the American Society of Clinical Oncology for a one-year term beginning in June 2015. She will take office as president-elect during ASCO's annual meeting in Chicago in June 2014.
ANDREA SLOAN, an ovarian cancer patient whose efforts to get access to a BioMarin drug attracted national media attention, died from complications of pneumonia Jan. 1 (The Cancer Letter, Nov. 8, 2013). Sloan, an Austin attorney, was 45.
The winners of the 2014 BREAKTHROUGH PRIZE in fundamental physics and life sciences were announced Dec. 12 at the NASA Ames Center, in Mountain View, Calif.
It takes a few clicks to look up the name of a company that holds the “Abbreviated New Drug Application,” or ANDA, to make a generic drug. Alas, this information is of little value.
Death rates continued to decline for all cancers combined for men and women of all major racial and ethnic groups and for most major cancer sites, according to the Annual Report to the Nation on the Status of Cancer. Rates for both sexes combined decreased by 1.5 percent per year from 2001 through 2010.
ISSUE 1 – JAN. 3, 2014 PDF Who Makes This Drug? Secretive Contract Manufacturing Arrangements Complicate Solutions to Shortages of Generics By Rena M. Conti The closing of Ben Venue Laboratories, a company that produces a large share of generic drugs used by America’s oncologists, brings into focus a little-understood business practice that exacerbates the […]
THOMAS BURKE stepped down as executive vice president and physician-in-chief at MD Anderson Cancer Center to accept the new position of executive vice president of the MD Anderson Cancer Network.
Guest Editorial Why I Don't Want to Pay for Your Horoscope: Reflections on FDA Warning to 23andMeBy Jim Evans
What Is and Isn't a Crime in TexasCPRIT Official Indicted for Skipping Peer ReviewBy Paul Goldberg
ISSUE 46 – DEC. 13, 2013 PDF CPRIT Official Indicted for Skipping Peer ReviewBy Paul Goldberg A grand jury in Travis County, Texas, indicted a former official of the Cancer Prevention and Research Institute of Texas for bypassing peer review in awarding an $11 million grant to a Dallas-based company. Why I Don’t Want to […]
